.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,063,832

« Back to Dashboard

Details for Patent: 7,063,832

Title:Delivery of muscle relaxants through an inhalation route
Abstract: The present invention relates to the delivery of muscle relaxants through an inhalation route. Specifically, it relates to aerosols containing muscle relaxants that are used in inhalation therapy. In a method aspect of the present invention, a muscle relaxant is delivered to a patient through an inhalation route. The method comprises: a) heating a coating of a muscle relaxant, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% muscle relaxant degradation products. In a kit aspect of the present invention, a kit for delivering a muscle relaxant through an inhalation route is provided which comprises: a) a coating of a muscle relaxant and b) a device for dispensing said coating a muscle relaxant as a condensation aerosol.
Inventor(s): Rabinowitz; Joshua D. (Mountain View, CA), Zaffaroni; Alejandro C. (Atherton, CA)
Assignee: Alexza Pharmaceuticals, Inc. (Palo Alto, CA)
Filing Date:Mar 31, 2004
Application Number:10/813,722
Claims:1. A method of treating musculoskeletal pain or restless leg syndrome in a patient comprising administering a therapeutic amount of a drug condensation aerosol to the patient by inhalation, wherein the drug is selected from the group consisting of quinine, chlorzoxazone, carisprodol and cyclobenzaprine, and wherein the condensation aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.

2. The method according to claim 1, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.

3. The method according to claim 1, wherein peak plasma drug concentration is reached in less than 0.1 hours.

4. The method according to claim 1, wherein the condensation aerosol is formed at a rate greater than 0.5 mg/second.

5. The method according to claim 1, wherein at least 50% by weight of the condensation aerosol is amorphous in form.

6. The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 50 mg and 500 mg of quinine delivered in a single inspiration.

7. The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 50 mg and 400 mg of chlorzoxazone delivered in a single inspiration.

8. The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 70 mg and 500 mg of carisprodol delivered in a single inspiration.

9. The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 2 mg and 25 mg of cyclobenzaprine delivered in a single inspiration.

10. A method of administering a drug condensation aerosol to a patient, comprising administering the drug condensation aerosol to the patient by inhalation, wherein the drug is selected from the group consisting of quinine, chlorzoxazone, carisprodol and cyclobenzaprine, and wherein the drug condensation aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% durg degradation products by weight, and an MMAD of less than 5 microns.

11. A kit for delivering a drug condensation aerosol comprising: a. a thin layer containing the drug, on a solid support, wherein the drug is selected from the group consisting of quinine, chlorzoxazone, carisprodol and cyclobenzaprine, and b. a device for providing the condensation aerosol, wherein the condensation aerosol is formed by heating the thin layer to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.

12. The kit according to claim 11, wherein the device comprises a. a flow through enclosure containing the solid support, b. a power source that can be activated to heat the solid support, and c. at least one portal through which air can be drawn by inhalation, wherein activation of the power source is effective to produce a vapor of the drug, and drawing air through the enclosure is effective to condense the vapor to form the condensation aerosol.

13. The kit according to claim 12, wherein the heat for heating the solid support is generated by an exothermic chemical reaction.

14. The kit according to claim 13, wherein the exothermic chemical reaction is oxidation of combustible materials.

15. The kit according to claim 12, wherein the heat for heating the solid support is generated by passage of current through an electrical resistance element.

16. The kit according to claim 12, wherein the solid support has a surface area dimensioned to accommodate a therapeutic dose of the drug.

17. The kit according to claim 11, wherein peak plasma drug concentration is reached in less than 0.1 hours.

18. The kit according to claim 11, further including instructions for use.

19. The method according to claim 1, wherein the condensation aerosol is characterized by an MMAD of 0.1 to 5 microns.

20. The method according to claim 2, wherein the condensation aerosol is characterized by an MMAD of about 0.2 to about 3 microns.

21. The method according to claim 10, wherein the drug is quinine.

22. The method according to claim 10, wherein the drug is chlorzoxazone.

23. The method according to claim 10, wherein the drug is carisprodol.

24. The method according to claim 10, wherein the drug is cyclobenzaprine.

25. The kit according to claim 11, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.

26. The kit according to claim 11 wherein the condensation aerosol is characterized by an MMAD of 0.1 to 5 microns.

27. The kit according to claim 11, wherein the condensation aerosol is characterized by an MMAD of about 0.2 to about 3 microns.

28. The kit according to claim 11, wherein the drug is quinine.

29. The kit according to claim 11, wherein the drug is chlorzoxazone.

30. The kit according to claim 11, wherein the drug is carisprodol.

31. The kit according to claim 11, wherein the drug is cyclobenzaprine.

32. The kit according to claim 12, wherein the solid support has a surface to mass ratio of greater than 1 cm.sup.2 per gram.

33. The kit according to claim 12, wherein the solid support has a surface to volume ratio of greater than 100 per meter.

34. The kit according to claim 12, wherein the solid support is a metal foil.

35. The kit according to claim 34, wherein the metal foil has a thickness of less than 0.25 mm.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc